All adjuvant therapies are based on the type of breast cancer diagnosed; for example, hormonal therapy (HT) is recommended for patients with tumors that are hormone receptor-positive for a duration of five to ten years post-surgery [24,25]. This evidence concerns the gene NR4A1 and breast carcinoma.